Justin Jarrell: Going beyond natural biology at AACRIO25
Justin Jarrell, Chief Commercial Officer at Teiko, shared a post on LinkedIn:
“At AACRIO25 this week, and a big theme I’m hearing is: going beyond natural biology.
Researchers are taking insights from syn-notch signaling, armored CARs, and orthogonal ligand-receptor systems to create the next generation of cell- and cytokine-based immunotherapies—designed, personalized, and tunable. These “unnatural” therapies (in the best way possible) are pushing the boundaries of what’s possible in science.
The synthetic immunotherapy pipeline is moving fast. Drug candidates built on these technologies are set to enter clinical trials within the next year or two, with a new wave of engineered immune therapies on the way. Labs at University of California, San Francisco, Stanford University, and Fred Hutch—led by Kole Roybal, Alex Marson, Chris Garcia, and Phil Greenberg, among others—are leading these tremendous innovations.
This is true out-of-the-box thinking (really, it’s out of this world) — working beyond the confines of natural biology and into entirely new therapeutic frontiers with big implications for the future. A decade ago, most of these approaches were just ideas—now, thanks to brilliant work supported by the NIH, government, and private sector, they’re already in the clinic.
What’s the most exciting synthetic immunotherapy innovation you’ve seen recently?
If you’re at AACRIO25, or the Bay Area, let’s connect!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023